Molina Healthcare - MOH Stock Forecast, Price & News

Molina Healthcare, Inc. provides managed health care services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. It operates in four segments, Medicaid, Medicare, Marketplace, and Other. As of December 31, 2021, the company served the company served approximately 5.2 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs in 18 states. The company was founded in 1980 and is headquartered in Long Beach, California.

Molina Healthcare Stock Performance

MOH traded up $2.73 during trading on Wednesday, hitting $329.77. 304,212 shares of the company traded hands, compared to its average volume of 491,651. Molina Healthcare has a one year low of $244.75 and a one year high of $350.19. The stock's fifty day moving average is $289.11 and its 200 day moving average is $306.14. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 0.84. The firm has a market cap of $19.16 billion, a P/E ratio of 25.47, a price-to-earnings-growth ratio of 1.12 and a beta of 0.85.

Molina Healthcare (NYSE:MOH - Get Rating) last released its earnings results on Wednesday, July 27th. The company reported $4.55 earnings per share for the quarter, beating analysts' consensus estimates of $4.34 by $0.21. The firm had revenue of $8.05 billion for the quarter, compared to analysts' expectations of $7.69 billion. Molina Healthcare had a net margin of 2.48% and a return on equity of 32.97%. The company's quarterly revenue was up 18.4% on a year-over-year basis. During the same period in the previous year, the company earned $3.40 earnings per share. As a group, equities analysts predict that Molina Healthcare will post 17.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Deutsche Bank Aktiengesellschaft boosted their target price on Molina Healthcare from $311.00 to $315.00 in a research report on Monday, August 1st. Loop Capital began coverage on Molina Healthcare in a research report on Thursday, June 16th. They issued a "hold" rating and a $310.00 target price for the company. Bank of America lowered Molina Healthcare from a "buy" rating to an "underperform" rating and decreased their price objective for the stock from $355.00 to $335.00 in a report on Thursday, May 26th. Cowen boosted their price objective on Molina Healthcare to $371.00 in a report on Tuesday. Finally, Cowen boosted their price objective on Molina Healthcare from $356.00 to $366.00 in a report on Monday, May 2nd. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Molina Healthcare currently has a consensus rating of "Moderate Buy" and a consensus target price of $341.00.

Insiders Place Their Bets

In other news, Director Ronna Romney sold 200 shares of the company's stock in a transaction on Monday, August 8th. The stock was sold at an average price of $327.04, for a total transaction of $65,408.00. Following the transaction, the director now owns 16,651 shares of the company's stock, valued at approximately $5,445,543.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP James Woys sold 25,000 shares of Molina Healthcare stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $328.11, for a total value of $8,202,750.00. Following the completion of the transaction, the executive vice president now directly owns 37,810 shares in the company, valued at approximately $12,405,839.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ronna Romney sold 200 shares of the firm's stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $327.04, for a total value of $65,408.00. Following the completion of the transaction, the director now owns 16,651 shares of the company's stock, valued at approximately $5,445,543.04. The disclosure for this sale can be found here. Insiders sold 27,200 shares of company stock valued at $8,924,138 over the last ninety days. 1.60% of the stock is currently owned by insiders.